Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Tokyo - Delayed Quote JPY

Daiichi Sankyo Company, Limited (4568.T)

3,316.00
+28.00
+(0.85%)
At close: 3:30:00 PM GMT+9
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 4568.T

Recent News: 4568.T

View More
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial
Clinical Trials Arena 2 days ago
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
Benzinga 3 days ago
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
Business Wire 3 days ago
TAK vs. DSNKY: Which Stock Is the Better Value Option?

TAK vs. DSNKY: Which Stock Is the Better Value Option?
Zacks 8 days ago
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
The Wall Street Journal 15 days ago
DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Business Wire 16 days ago
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
Pharmaceutical Technology 20 days ago
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
Business Wire 20 days ago
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
Zacks 24 days ago
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
Business Wire 24 days ago
TAK or DSNKY: Which Is the Better Value Stock Right Now?

TAK or DSNKY: Which Is the Better Value Stock Right Now?
Zacks last month
View More

Related Tickers

4519.T Chugai Pharmaceutical Co., Ltd.
8,251.00
+0.70%
 
AZN.ST AstraZeneca PLC
1,337.00
+0.94%
 
4503.T Astellas Pharma Inc.
1,360.50
-0.55%
 
AZNCF AstraZeneca PLC
135.75
0.00%
 
ORNBV.HE Orion Oyj
53.55
+6.78%
 
AZN AstraZeneca PLC
69.28
+1.12%
 
LILY34.SA Eli Lilly and Company
161.28
+3.04%
 
AZN.L AstraZeneca PLC
10,444.00
+0.79%
 
ROG.SW Roche Holding AG
262.30
+1.63%
 
CHGCY Chugai Pharmaceutical Co., Ltd.
29.56
+2.14%